Immune cells
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients undergoing cardiac surgery with cardiopulmonary bypass; 2) Aged 18-75 years, regardless of gender; 3) Understand the purpose of this trial and voluntarily participate, and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1) Pregnant or breastfeeding women; 2) Participation in other interventional clinical trials within 30 days prior to surgery or during hospitalization; 3) Comorbid immune system diseases, including but not limited to AIDS, Graves' disease, Hashimoto's thyroiditis, systemic lupus erythematosus, nephrotic syndrome, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, scleroderma, Crohn's disease, ulcerative colitis; use of immunosuppressive drugs within six months prior to admission, including monoclonal antibodies, polyclonal antibodies, antimetabolites, alkylating agents, microbial metabolites; or receiving radiation therapy; 4) Presence of malignant tumors in any location; 5) Presence of hematological diseases, including but not limited to aplastic anemia, thalassemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia; or comorbid other severe coagulopathy disorders, and currently undergoing anticoagulation therapy; 6) History of organ transplantation or bone marrow transplantation; 7) Unable to obtain informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fibrin-positive cells; | — |
Secondary
| Measure | Time frame |
|---|---|
| Activated leukocytes; | — |
Countries
China
Contacts
West China Hospital, Sichuan University